Evidence map›Paper›PMID 27760566›Full record

ArticleJournal of hematology & oncology2016

MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis.

Yingmei Wang, Limei Hu, Ping Ji, Fei Teng, Wenyan Tian, Yuexin Liu, David Cogdell, Jinsong Liu, Anil K Sood, Russell Broaddus and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. RhoG-ELMO1-RAC1 is involved in phagocytosis suppressed by mono-butyl phthalate in TM4 cells.Environmental science and pollution research international · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yingmei WangDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China. wangyingmei1978@126.com.
Limei HuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping JiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fei TengDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.
Wenyan TianDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuexin LiuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David CogdellDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jinsong LiuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Russell BroaddusDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fengxia XueDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China. fengxiaxue1962@gmail.com.
Wei ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wezhang@wakehealth.edu.
The University of Texas MD Anderson Cancer Center · USTianjin Medical University General Hospital · CNAtrium Health Wake Forest Baptist · USThe University of Texas Medical Branch at Galveston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundEndometrial carcinoma (EC) is one of the most common malignancies of the female reproductive system. Migration and invasion inhibitory protein (MIIP) gene was recently discovered candidate tumor suppress gene which located at chromosome 1p36.22. 1p36 deletion was found in many types of tumor including EC. In the present study, we will determine the role and mechanism of MIIP in EC metastasis.

methodsImmunohistochemistry was used to measure MIIP expression in normal and EC tissue. Both gain-of-function (infection) and loss-of-function (siRNA) assays were used to alter MIIP expression levels. The effect of MIIP on cell migration and invasion was measured by transwell assay. F-actin immunofluorescence staining was used to observe the cell morphology. The activation of GTP-loaded Rac1 was evaluated by Rac activity assay kit. Immunoprecipitation/WB was used to measure the interaction between MIIP and PAK1.

resultsWe demonstrate that MIIP expression was significantly decreased in EC patients comparing to the normal ones, and decreased MIIP expression in EC tissues is associated with deep myometrial invasion, advanced stage, and the presence of lymph node metastasis. Using both gain-of-function (infection) and loss-of-function (siRNA) assays, we show that MIIP markedly blocked EC cell migration, whereas loss of MIIP led to increase in EC cell migration. We demonstrate that elevated expression of MIIP resulted in cytoskeleton reorganization with decreased formation of lamellipodia. We also provide evidence that MIIP is a key molecule in directing Rac1 signaling cascades in EC. Ectopically expressed MIIP consistently competed with Rac1-GTP for binding with the PAK1 p21-binding domain. Our data show that MIIP and PAK1 bind each other and that a C-terminal polyproline domain of MIIP is required for PAK1 binding. Deletion of the PAK1-binding domain of MIIP reduced cell migration-inhibiting activity.

conclusionsMIIP may function as a tumor suppressor gene for endometrial carcinoma. MIIP attenuates Rac1 signaling through a protein interaction network, and loss of this regulator may contribute to EC metastasis.

Indexed as

Neoplasm MetastasisCarrier ProteinsCell Line, TumorCell MovementCell ShapeCytoskeletonEndometrial NeoplasmsFemaleGenes, Tumor SuppressorHumansIntracellular Signaling Peptides and ProteinsLymphatic MetastasisNeoplasm Invasivenessp21-Activated KinasesProtein BindingPseudopodiaCarrier ProteinsIntracellular Signaling Peptides and ProteinsMIIP protein, humanp21-Activated KinasesPAK1 protein, humanrac1 GTP-Binding ProteinRAC1 protein, humanRNA, Small InterferingEndometrial cancerMigrationMIIPRac1/PAK1 pathwayTumor suppressor gene

Identifiers

PMID27760566
PMCPMC5069779
OpenAlexW2534484160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.